The historical rank and industry rank for Teva Pharmaceutical Industries's Net Margin % or its related term are showing as below:
BSP:T1EV34'
s Net Margin % Range Over the Past 10 Years
Min: -74.43 Med: -7.92 Max: 9.02
Current: 9.02
BSP:T1EV34's Net Margin % is ranked better than 60.44% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs BSP:T1EV34: 9.02
Teva Pharmaceutical Industries (BSP:T1EV34) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Teva Pharmaceutical Industries Net Margin % Related Terms
Teva Pharmaceutical Industries Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:T1EV34 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Net Margin % distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (BSP:T1EV34) has a Net Margin % of 9.27% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Teva Pharmaceutical Industries and its competitors. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #377 out of 953 companies in the Drug Manufacturers industry, placing it in the top 39.6%.
Is Teva Pharmaceutical Industries' Net Margin % too high?
Teva Pharmaceutical Industries' current Net Margin % is 9.27%. The Drug Manufacturers industry median Net Margin % is 5.69. Teva Pharmaceutical Industries' value of 9.27% is 62.9% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #377 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #377 out of 953 companies for Net Margin %. This puts Teva Pharmaceutical Industries in the upper half of its industry. The industry median Net Margin % is 5.69. Teva Pharmaceutical Industries' value of 9.27% is 62.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current Net Margin % of 9.27% is 62.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current Net Margin % is 9.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Teva Pharmaceutical Industries (BSP:T1EV34) has a current Net Margin % of 9.27%. The stock's GF Value™ is R$51.72, compared to a current price of R$85.99 — trading 66.3% above its estimated fair value. The current Net Margin % is 9.27% and 62.9% above the Drug Manufacturers industry median of 5.69. Teva Pharmaceutical Industries' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current Net Margin % is 9.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of R$85.99 is trading 66.3% above its estimated GF Value™ of R$51.72.
Key valuation signals for BSP:T1EV34:
Net Margin %: 9.27%
GF Value™: R$51.72 vs. price of R$85.99 (66.3% above fair value)
Industry Position: 62.9% above the Drug Manufacturers median (#377 of 953)
No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical Industries Business Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
59GF Score
Get the complete analysis for BSP:T1EV34
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:T1EV34 has been successfully added to your 
